ESPR Esperion Therapeutics Inc.

43.51
-0.41  -1%
Previous Close 43.92
Open 43.71
Price To Book -23.91
Market Cap 1,201,634,423
Shares 27,617,431
Volume 481,793
Short Ratio
Av. Daily Volume 781,384
Stock charts supplied by TradingView

NewsSee all news

  1. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., May 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that, on May 15, 2020, the Compensation Committee of Esperion's Board of Directors granted 88,902 restricted stock units (RSUs)

  2. Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference

    ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA

  3. Esperion Reports First Quarter 2020 Financial Results and Provides Company Update

    Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in EuropeNEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March

  4. Esperion to Report First Quarter 2020 Financial Results May 6, 2020

    ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following

  5. Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan

    –  Esperion to Receive $60 Million Upfront Payment  – –  Up to $510 Million in Total Milestones  – –  Substantial Tiered Royalties  – –  Combines Esperion's Expertise in Lipid Management with Otsuka's Deep

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced February 26, 2020.
Bempedoic Acid/ Ezetimibe
Hypercholesterolemia
FDA Approval announced February 21, 2020.
Bempedoic acid
Hypercholesterolemia
Phase 2 trial met primary endpoint - August 29, 2019.
Bempedoic Acid/ Ezetimibe (1002-058)
LDL-C and type 2 diabetes
Phase 3 completion of enrolment announced September 5, 2019. Trial to be completed in 2H 2022.
Bempedoic Acid (ETC-1002) CLEAR Outcomes
Cardiovascular Diseases

Latest News

  1. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., May 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that, on May 15, 2020, the Compensation Committee of Esperion's Board of Directors granted 88,902 restricted stock units (RSUs)

  2. Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference

    ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA

  3. Esperion Reports First Quarter 2020 Financial Results and Provides Company Update

    Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in EuropeNEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March

  4. Esperion to Report First Quarter 2020 Financial Results May 6, 2020

    ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020. Following

  5. Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan

    –  Esperion to Receive $60 Million Upfront Payment  – –  Up to $510 Million in Total Milestones  – –  Substantial Tiered Royalties  – –  Combines Esperion's Expertise in Lipid Management with Otsuka's Deep

  6. Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference

    ANN ARBOR, Mich., April 09, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 19th

  7. Esperion Therapeutics shares are trading higher after the company announced European Commission approval of its NILEMDO tablet.

  8. Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

    – First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option –– Esperion Aims to Set New Industry Standard by Pricing NEXLETOL for

  9. Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology's 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)

    ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of

  10. Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of the NEXLETOL™ (bempedoic acid) Tablet and Phase 2 Study Results of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet to be Presented at the American College of Cardiology's 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)

    ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of

  11. Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors

    ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On

  12. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that, on February 26, 2020, the Compensation Committee of Esperion's Board of Directors granted non-qualified stock options to

  13. Esperion to Participate in Upcoming Investor Conferences

    ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Cowen 40th Annual Health Care Conference in

  14. Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results

    ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31, 2019. "2019 was a

  15. Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

    - NEXLIZET Lowered LDL-C by 38 Percent Compared to Placebo when Added on to Maximally Tolerated Statins -- First Non-Statin, LDL-Cholesterol Lowering Combination Medicine Ever Approved -- Esperion's Second Oral,

  16. Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

    – First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients –– NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism –– Fills an Unmet

  17. Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

    –  Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism  ––  Positive CHMP Opinion is Based on the Completed

  18. Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

    –  Bempedoic Acid is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism ––  Positive CHMP Opinion is Based on the Completed Pivotal Phase 3 LDL-Cholesterol Lowering

  19. Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference

    ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P. Morgan Healthcare

  20. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that, on January 2, 2020, the Compensation Committee of Esperion's Board of Directors granted 358 restricted stock units (RSUs)

  21. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion's Board of Directors granted 61,705 restricted stock units

  22. Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

    ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association

  23. Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

     –  Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – –  Over 52-Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to Placebo – – Bempedoic

  24. Esperion to Participate in Upcoming Investor Conferences

    ANN ARBOR, Mich., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28th Annual Healthcare

  25. Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

    ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019. "The

  26. Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions

    ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association

  27. Esperion to Report Third Quarter 2019 Financial Results November 6, 2019

    ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open. Bempedoic Acid

  28. Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List

    ANN ARBOR, Mich., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the "Top 10 Medical Innovations for 2020" at Cleveland Clinic's 2019 Medical Innovation Summit on

  29. Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid

    – 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial –– Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE

  30. Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    ANN ARBOR, Mich., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that, on August 27, 2019, the Compensation Committee of Esperion's Board of Directors granted non-qualified stock options to

  31. Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes

    — Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control —— Overall Adverse Events Comparable to Placebo